Tag: hbv capsid inhibitors market forecast

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Size Forecast: How Big Could The Market Get By 2030?

The hepatitis b virus (hbv) capsid inhibitors market size has experienced significant expansion in recent years. It is projected to escalate from $0.52 billion in 2025 to $0.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. The historical growth observed in this sector was driven by factors including the worldwide impact of chronic hepatitis B infection, the deficiencies of current antiviral treatments, the initial clinical verification of capsid inhibitors, augmented funding for virology research, and increasing engagement in pharmaceutical pipeline development.

The hepatitis b virus (hbv) capsid inhibitors market size is projected to experience rapid expansion over the coming years. Its valuation is anticipated to reach $0.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. This projected growth during the forecast period is attributable to several factors, including the increasing use of combination regimens with immunotherapies, a surge in investment directed towards curative hbv treatments, a rise in regulatory approvals for innovative antivirals, the expansion of global screening initiatives, and advancements in next-generation capsid inhibitors. Key developments expected within this period involve an escalating focus on functional cure strategies for hbv, the increasing creation of capsid assembly modulators, a growing adoption of combination therapy approaches, the expansion of late-stage clinical pipelines, and improved targeting of viral replication pathways.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=84674280&type=smp&name=Hepatitis%20B%20Virus%20%28HBV%29%20Capsid%20Inhibitors%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Hepatitis B Virus (HBV) Capsid Inhibitors Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The expanding occurrence of hepatitis B virus infections is anticipated to boost the hepatitis B virus (HBV) capsid inhibitors market in the future. Hepatitis B Virus (HBV) infections are liver ailments stemming from the hepatitis B virus, capable of causing both short-term and long-term illnesses. These infections spread via exposure to contaminated blood or bodily fluids, potentially leading to severe issues like liver cirrhosis or liver cancer. The rising incidence of Hepatitis B Virus (HBV) infections is primarily attributable to insufficient vaccination rates, leaving many unprotected and facilitating the virus’s transmission through contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors combat hepatitis B virus (HBV) infections by interfering with the viral capsid’s formation and assembly, which in turn halts viral replication and curtails the infection’s dissemination throughout the body. For example, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental body, in April 2024, indicated that by the close of 2022, merely 13% of those with chronic hepatitis B had been diagnosed, and roughly 3% (7 million) had undergone antiviral therapy. Regarding hepatitis C, 36% of affected persons were diagnosed, with 20% (12.5 million) getting curative treatment. These statistics fall significantly short of the worldwide goal to treat 80% of individuals with chronic hepatitis B and C by 2030. Consequently, the rising prevalence of hepatitis B virus infections is fueling the expansion of the hepatitis B virus (HBV) capsid inhibitors market.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Segment Outlook: Which Categories Are Growing Fastest?

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

Hepatitis B Virus (HBV) Capsid Inhibitors Market Innovation Trends Shaping Future Development

Leading companies within the hepatitis B virus (HBV) capsid inhibitors market are focusing on innovations, including oral small molecule capsid assembly modulators, to enhance antiviral effectiveness, improve patient adherence, and achieve sustained viral suppression. These oral small-molecule capsid assembly modulators are orally administered antiviral agents designed to disrupt the assembly of the hepatitis B virus (HBV) capsid, thereby blocking its replication and reducing viral activity in the body. For example, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to initiate a clinical trial. This trial aims to evaluate innovative treatment candidates for chronic hepatitis B (CHB), leveraging Aligos’s advanced capsid assembly modulator technology to boost antiviral efficacy and accelerate the development of next-generation HBV therapies. This launch signifies a key progression in Aligos’s objective to develop effective and potentially curative treatments for patients living with chronic hepatitis B.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Leading Companies And Competitive Benchmarking

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

View The Full Hepatitis B Virus (HBV) Capsid Inhibitors Market Report:

https://thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Hepatitis B Virus (HBV) Capsid Inhibitors Market Regional Outlook: Where Is Opportunity Concentrated?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Revenue Growth Supported By A CAGR Of 0.97% Through 2030

The market for hepatitis B virus (HBV) capsid inhibitors has experienced rapid expansion in recent years. Projections indicate it will increase from $0.52 billion in 2025 to $0.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. This historical growth has been driven by the worldwide prevalence of chronic hepatitis B infections, the shortcomings of current antiviral treatments, initial clinical successes with capsid inhibitors, enhanced financial support for virology research, and a surge in pharmaceutical pipeline developments.

In the coming years, the market for hepatitis B virus (HBV) capsid inhibitors is poised for notable expansion, with projections indicating it will reach a value of $0.98 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.4%. The anticipated growth during this forecast period can be traced to several key drivers, including the broadening scope of combination therapies involving immunotherapies, increased financial commitments directed toward developing curative HBV treatments, a rising number of regulatory approvals granted for new antiviral agents, the expansion of global screening initiatives, and the progress being made with next-generation capsid inhibitors. Among the prominent trends shaping this period are a heightened emphasis on achieving functional cures for HBV infections, accelerated development of capsid assembly modulators, a growing adoption of combination therapy strategies, the broadening of late-stage clinical pipelines, and more refined efforts directed at disrupting viral replication mechanisms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Hepatitis B Virus (HBV) Capsid Inhibitors Market Growth Factors Supporting Long-Term Expansion

The hepatitis B virus (HBV) capsid inhibitors market is anticipated to be driven forward by the rising incidence of hepatitis B infections. These infections, which affect the liver and are transmitted through exposure to infected blood or bodily fluids, can result in acute or chronic diseases, ultimately leading to severe outcomes such as liver cirrhosis or cancer. This growing prevalence is largely attributed to inadequate vaccination coverage, leaving many individuals vulnerable and facilitating the virus’s transmission via infected blood or bodily fluids. HBV capsid inhibitors work by interfering with the viral capsid’s formation and assembly, thereby halting viral replication and curbing the infection’s spread throughout the body. In April 2024, a report from the World Health Organization (WHO), an intergovernmental body based in Switzerland, indicated that by the end of 2022, merely 13% of chronic hepatitis B cases had been identified, with only about 3% (7 million people) undergoing antiviral therapy. For hepatitis C, 36% of those affected had been diagnosed, and 20% (12.5 million) received curative treatment—numbers that fall well short of the 2030 global objective to treat 80% of individuals with chronic hepatitis B and C. Consequently, the escalating prevalence of hepatitis B virus infections is fueling expansion in the HBV capsid inhibitors market.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Segmentation And Category Breakdown

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

Hepatitis B Virus (HBV) Capsid Inhibitors Market Industry Trends Shaping Future Revenue Growth

Key players in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing innovations like oral small molecule capsid assembly modulators to boost antiviral effectiveness, improve patient adherence, and maintain long-term viral suppression. These oral small-molecule capsid assembly modulators are antiviral drugs taken by mouth that disrupt the formation of the HBV capsid, thereby halting viral replication and decreasing viral presence in the body. A notable example occurred in July 2024, when Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical firm, partnered with Xiamen Amoytop Biotech Co., Ltd., a Chinese biopharmaceutical company, to initiate a clinical trial assessing novel treatment options for chronic hepatitis B (CHB). This collaboration aims to utilize Aligos’s sophisticated capsid assembly modulator technology to improve antiviral outcomes and speed up the creation of next-generation HBV therapies. This initiative represents a major milestone in Aligos’s pursuit of developing effective, potentially curative solutions for individuals living with chronic hepatitis B.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Analysis Of Major Industry Participants

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Access The Complete Hepatitis B Virus (HBV) Capsid Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Hepatitis B Virus (HBV) Capsid Inhibitors Market Regional Analysis: Which Region Leads By Revenue?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Hepatitis B Virus (HBV) Capsid Inhibitors Market During The 2026–2030 Period?

The hepatitis b virus (hbv) capsid inhibitors market size has seen swift expansion in recent years. This market is set to increase from $0.52 billion in 2025 to $0.59 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.7%. The surge observed in the past can be ascribed to the extensive global impact of chronic hepatitis B infection, the inadequacies of current antiviral treatments, the early positive clinical validation of capsid inhibitors, heightened funding for virology research, and increasing activity within pharmaceutical pipelines.

The hepatitis b virus (hbv) capsid inhibitors market is projected to experience substantial growth in the upcoming years. By 2030, its value is expected to reach **$0.98 billion**, demonstrating a compound annual growth rate (CAGR) of **13.4%**. This anticipated expansion during the forecast period is attributed to the increased adoption of combination regimens with immunotherapies, growing investment in curative HBV treatments, a rise in regulatory approvals for innovative antivirals, expanding global screening programs, and advancements in next-generation capsid inhibitors. Key trends for this period include a heightened focus on functional cure strategies for HBV, accelerated development of capsid assembly modulators, evolving combination therapy approaches, the expansion of late-stage clinical pipelines, and improved targeting of viral replication pathways.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp

Which Growth Drivers Are Expected To Support The Hepatitis B Virus (HBV) Capsid Inhibitors Market Forward?

The rising incidence of hepatitis B virus infections is projected to fuel expansion within the hepatitis B virus (HBV) capsid inhibitors market in the coming period. Hepatitis B Virus (HBV) infections are defined as hepatic ailments triggered by the hepatitis B virus, capable of manifesting as acute or long-term conditions. These infections transmit via exposure to contaminated blood or bodily fluids and can culminate in severe health issues like liver cirrhosis or liver cancer. The heightened occurrence of Hepatitis B Virus (HBV) infections largely stems from inadequate vaccination rates, leaving significant segments of the populace vulnerable and facilitating the virus’s transmission via contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors combat hepatitis B virus (HBV) infections by interfering with the development and construction of the viral capsid, consequently hindering viral replication and decreasing the dissemination of the infection internally. As an illustration, a report released by the World Health Organization (WHO), a Switzerland-based intergovernmental body, in April 2024, indicated that by the end of 2022, merely 13% of those suffering from chronic hepatitis B had been diagnosed, with around 3% (7 million) having undergone antiviral therapy. Regarding hepatitis C, 36% of impacted individuals had received a diagnosis, and 20% (12.5 million) were undergoing curative treatment. These figures fall significantly short of the worldwide objective to treat 80% of individuals with chronic hepatitis B and C by 2030. Consequently, the expanding prevalence of hepatitis B virus infections is propelling the advancement of the hepatitis B virus (HBV) capsid inhibitors market.

What Segment Categories Are Evaluated In The Hepatitis B Virus (HBV) Capsid Inhibitors Market Study?

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

What Trends Are Influencing The Future Of The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Leading companies active in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing the advancement of technologies such as oral small molecule capsid assembly modulators. These innovations are being developed to improve antiviral efficacy, enhance patient compliance, and achieve sustained viral suppression. Oral small-molecule capsid assembly modulators are characterized as antiviral agents taken by mouth that interfere with the assembly process of the hepatitis B virus (HBV) capsid, consequently blocking its replication and reducing viral activity in the body. For instance, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company. This collaboration led to the launch of a clinical trial designed to evaluate pioneering treatment candidates for chronic hepatitis B (CHB), with the goal of leveraging Aligos’s sophisticated capsid assembly modulator technology to increase antiviral efficacy and accelerate the development of next-generation HBV therapies. This launch signifies a key progression in Aligos’s mission to create effective and potentially curative treatments for patients living with chronic hepatitis B.

Which Organizations Are Involved In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Access The Complete Hepatitis B Virus (HBV) Capsid Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report

What Is The Largest Regional Market In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Hepatitis B Virus (HBV) Capsid Inhibitors Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp

Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Capsid Inhibitors Market 2026, By The Business Research Company

Hepatitis B Virus Hbv Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Chronic Hepatitis B Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Hepatitis B Virus (HBV) Capsid Inhibitors Market Expected To Reach Based On Its 2026 Value?

The hepatitis b virus (hbv) capsid inhibitors market has experienced substantial growth in recent years. This market is projected to expand from $0.52 billion in 2025 to $0.59 billion in 2026, at a compound annual growth rate (CAGR) of 13.7%. The historical growth can be ascribed to the global burden of chronic hepatitis b infection, limitations of existing antiviral therapies, early clinical validation of capsid inhibitors, increased virology research funding, and growing pharmaceutical pipeline activity.

The hepatitis b virus (hbv) capsid inhibitors market is anticipated to experience swift expansion in the coming years. Its value is projected to reach $0.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. This projected growth during the forecast period is fueled by factors such as the broader adoption of combination regimens involving immunotherapies, increased financial commitments to curative HBV therapies, a rise in regulatory clearances for new antivirals, expanding worldwide screening initiatives, and progress in next-generation capsid inhibitors. Key developments anticipated during this period encompass a heightened emphasis on functional cure strategies for HBV, the escalating development of capsid assembly modulators, evolving combination therapy methods, an expansion of late-stage clinical trial pipelines, and improved targeting of pathways involved in viral replication.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp

Which Important Drivers Are Guiding The Hepatitis B Virus (HBV) Capsid Inhibitors Market Growth?

The growing incidence of hepatitis B virus infections is anticipated to boost the hepatitis B virus (HBV) capsid inhibitors market. Hepatitis B Virus (HBV) infections are liver ailments caused by the hepatitis B virus, leading to both acute and chronic conditions. These infections spread through contact with infected blood or bodily fluids and can result in severe complications such as liver cirrhosis or liver cancer. The increasing prevalence of Hepatitis B Virus (HBV) infections is primarily due to insufficient vaccination coverage, leaving a significant portion of the population unprotected and facilitating easier viral transmission via infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors address hepatitis B virus (HBV) infections by disrupting the formation and assembly of the viral capsid, thereby inhibiting viral replication and reducing the spread of infection within the body. For instance, in April 2024, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, highlighted that by the end of 2022, only 13% of individuals with chronic hepatitis B had been diagnosed, and approximately 3% (7 million) had received antiviral treatment. For hepatitis C, 36% of affected individuals were diagnosed, with 20% (12.5 million) receiving curative therapy. These figures remain well below the global target of treating 80% of people living with chronic hepatitis B and C by 2030. Therefore, the increasing prevalence of hepatitis B virus infections is driving the expansion of the hepatitis B virus (HBV) capsid inhibitors market.

How Is Segmentation Applied In The Hepatitis B Virus (HBV) Capsid Inhibitors Market Segment Analysis?

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

Which Trends Are Contributing To Changes In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Key companies active in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing the development of innovations, such as oral small molecule capsid assembly modulators, to enhance antiviral efficacy, boost patient compliance, and achieve lasting viral suppression. Oral small-molecule capsid assembly modulators are orally administered antiviral agents that disrupt the assembly of the hepatitis B virus (HBV) capsid, thereby blocking its replication and decreasing viral activity in the body. For example, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to commence a clinical trial evaluating novel treatment candidates for chronic hepatitis B (CHB). This initiative aims to leverage its advanced capsid assembly modulator technology to improve antiviral effectiveness and accelerate the development of next-generation HBV therapies. This launch signifies a vital step in advancing Aligos’s commitment to developing effective and potentially curative treatments for patients experiencing chronic hepatitis B.

Who Are The Companies Participating In The Hepatitis B Virus (HBV) Capsid Inhibitors Market Environment?

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Get The Full Hepatitis B Virus (HBV) Capsid Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report

Which Region Has The Greatest Market Share In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Hepatitis B Virus (HBV) Capsid Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report

Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Capsid Inhibitors Market 2026, By The Business Research Company

Hepatitis B Virus Hbv Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Chronic Hepatitis B Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Hepatitis B Virus (HBV) Capsid Inhibitors Market By The End Of 2030?

The market size for hepatitis b virus (hbv) capsid inhibitors has seen rapid expansion over recent years. This market is forecast to increase from $0.52 billion in 2025 to $0.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. The historical growth can be linked to the global burden of chronic hepatitis B infection, the limitations inherent in existing antiviral therapies, the early clinical validation of capsid inhibitors, augmented funding for virology research, and heightened pharmaceutical pipeline activity.

The hepatitis b virus (hbv) capsid inhibitors market size is anticipated to expand significantly over the next few years, projected to reach $0.98 billion in 2030, growing at a compound annual growth rate (CAGR) of 13.4%. This projected growth is driven by the wider adoption of combination regimens with immunotherapies, increased investment in curative HBV treatments, a rise in regulatory approvals for innovative antivirals, expanding global screening programs, and advancements in next-generation capsid inhibitors. Important trends for this forecast period include an intensified focus on functional cure strategies for HBV, the increasing development of capsid assembly modulators, a growing reliance on combination therapy approaches, the expansion of late-stage clinical pipelines, and improved targeting of viral replication pathways.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

The expansion of the hepatitis B virus (HBV) capsid inhibitors market is anticipated to be fueled by the rising occurrence of hepatitis B virus infections. These infections are liver-related conditions instigated by the hepatitis B virus, capable of progressing into acute or chronic ailments. They propagate through exposure to contaminated blood or bodily fluids, potentially leading to severe issues like liver cirrhosis or liver cancer. The primary reason for this growing prevalence of Hepatitis B Virus (HBV) infections stems from insufficient vaccination rates, leaving a significant part of the population vulnerable and facilitating simpler viral transmission via contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors combat these infections by interfering with the viral capsid’s formation and assembly, which in turn halts viral replication and diminishes the infection’s dissemination throughout the body. A notable example from April 2024, based on a World Health Organization (WHO) report, indicated that by the close of 2022, merely 13% of chronic hepatitis B patients had been diagnosed, and around 3% (7 million) had undergone antiviral therapy. For hepatitis C, diagnoses stood at 36% of affected individuals, with 20% (12.5 million) receiving curative treatment. These figures fall significantly short of the global objective to treat 80% of individuals with chronic hepatitis B and C by 2030. Consequently, the rising occurrence of hepatitis B virus infections is a key driver for the expansion of the hepatitis B virus (HBV) capsid inhibitors market.

Which Segment Classifications Shape The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

How Are Trends Impacting The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Leading companies in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing advancements like oral small molecule capsid assembly modulators to boost antiviral effectiveness, improve patient adherence, and achieve lasting viral suppression. Oral small-molecule capsid assembly modulators are defined as antiviral medications administered orally, designed to disrupt the assembly of the hepatitis B virus (HBV) capsid, thereby hindering its replication and diminishing viral load in the body. As an illustration, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical entity, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical firm, to initiate a clinical trial. This trial aims to assess novel treatment candidates for chronic hepatitis B (CHB), intending to utilize its sophisticated capsid assembly modulator technology to improve antiviral efficacy and expedite the creation of future HBV therapies. This launch represents a crucial progression in Aligos’s objective to develop potent and potentially curative treatments for individuals with chronic hepatitis B.

Which Companies Are Expanding Their Footprint In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Read the full hepatitis b virus (hbv) capsid inhibitors market report here:

https://www.thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report

Which Regions Are Projected To Dominate The Hepatitis B Virus (HBV) Capsid Inhibitors Market In The Coming Years?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hepatitis B Virus (HBV) Capsid Inhibitors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30294&type=smp

Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Capsid Inhibitors Market 2026, By The Business Research Company

Hepatitis B Virus Hbv Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Chronic Hepatitis B Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the hepatitis b virus (hbv) capsid inhibitors market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Hepatitis B Virus (HBV) Capsid Inhibitors Market between 2026 and 2030?

The hepatitis b virus (hbv) capsid inhibitors market has experienced substantial growth in recent years. Projections indicate it will expand from $0.52 billion in 2025 to $0.59 billion in 2026, showing a compound annual growth rate (CAGR) of 13.7%. This historical growth can be attributed to the global burden of chronic hepatitis b infection, limitations of existing antiviral therapies, early clinical validation of capsid inhibitors, increased virology research funding, and growing pharmaceutical pipeline activity.

The hepatitis b virus (HBV) capsid inhibitors market size is projected to experience significant growth in the upcoming years. It is expected to expand to $0.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.4%. This anticipated growth can be attributed to factors such as the broader implementation of combination regimens with immunotherapies, increasing investments in curative HBV treatments, a rise in regulatory approvals for novel antiviral compounds, the expansion of global screening programs, and advancements in next-generation capsid inhibitors. Prominent trends throughout the forecast period include an intensified focus on functional cure strategies for HBV, the accelerated development of capsid assembly modulators, an increase in combination therapy approaches, the expansion of late-stage clinical pipelines, and more effective targeting of viral replication pathways.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp

Which Drivers Are Expected To Impact The Hepatitis B Virus (HBV) Capsid Inhibitors Market During The Forecast Period?

The escalating occurrence of hepatitis B virus infections is projected to drive the expansion of the hepatitis B virus (HBV) capsid inhibitors market moving forward. Hepatitis B Virus (HBV) infections are defined as liver infections caused by the hepatitis B virus, which can lead to both acute and chronic conditions. These infections spread through exposure to infected blood or bodily fluids and can result in grave complications such as liver cirrhosis or liver cancer. The primary cause for the rising prevalence of Hepatitis B Virus (HBV) infections is inadequate vaccination coverage, leaving substantial segments of the population unprotected and enabling easier transmission of the virus via contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors address hepatitis B virus (HBV) infections by interfering with the formation and assembly of the viral capsid, thereby preventing viral replication and reducing the propagation of infection within the body. For example, in April 2024, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated that as of the end of 2022, only 13% of individuals living with chronic hepatitis B had been diagnosed, and roughly 3% (7 million) had received antiviral treatment. For hepatitis C, 36% of affected individuals had been diagnosed, with 20% (12.5 million) receiving curative therapy, figures that remain considerably below the global goal of treating 80% of people living with chronic hepatitis B and C by 2030. Therefore, the increasing prevalence of hepatitis B virus infections is stimulating the growth of the hepatitis B virus (HBV) capsid inhibitors market.

How Is The Hepatitis B Virus (HBV) Capsid Inhibitors Market Divided Into Segments?

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

Which Trends Are Influencing The Performance And Direction Of The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Leading companies in the hepatitis B virus (HBV) capsid inhibitors market are concentrating on advancing innovations such as oral small molecule capsid assembly modulators, intending to boost antiviral effectiveness, improve patient adherence, and achieve lasting viral suppression. Oral small-molecule capsid assembly modulators are characterized as antiviral agents administered orally that disrupt the assembly of the hepatitis B virus (HBV) capsid, thereby preventing its replication and reducing viral activity in the body. For instance, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to commence a clinical trial evaluating novel treatment candidates for chronic hepatitis B (CHB). This initiative aims to utilize Aligos’s advanced capsid assembly modulator technology to enhance antiviral efficacy and expedite the development of next-generation HBV therapies. This launch signifies a key development in Aligos’s commitment to creating effective and potentially curative treatments for chronic hepatitis B patients.

Which Leading Companies Dominate The Hepatitis B Virus (HBV) Capsid Inhibitors Market Share?

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report

How Does The Hepatitis B Virus (HBV) Capsid Inhibitors Market Perform Across Major Global Regions?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hepatitis B Virus (HBV) Capsid Inhibitors Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30294&type=smp

Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Capsid Inhibitors Market 2026, By The Business Research Company

Hepatitis B Virus Hbv Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Chronic Hepatitis B Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model